ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements with these filters
Ishita Drugs & Industries Ltd reported revenue from operations of ₹3 Cr (-3.2% YoY) and net profit of ₹0.2 Cr (+100.0% YoY) for Q2 FY27.
Ishita Drugs & Industries will hold a board meeting on 03/11/2026 to approve Q1 FY2027 unaudited results. The filing is a prior intimation under Regulation 29 of SEBI LODR.
Ishita Drugs & Industries Ltd submitted its quarterly shareholding pattern under Regulation 31, disclosing the promoter and public shareholdings as of September 30, 2026.
Ishita Drugs and Industries Limited has re-appointed Mrs. Abha Agrawal as a Non-Executive Non-Independent Director. The company also re-appointed M/s. Jaymin Shah & Associates as Statutory Auditors.
Ishita Drugs & Industries Ltd has re-appointed M/s. Jaymin Shah & Associates as its Statutory Auditor from the 33rd to the 34th AGM.
Ishita Drugs & Industries Ltd. held its 33rd Annual General Meeting on September 30, 2026. The meeting covered financial statements, auditor appointments, and director re-appointment.
Ishita Drugs approved Rs.11.75 Crore borrowings from HDFC Bank, covering a term loan and working capital facility. This is within shareholder-approved borrowing limits from its 31st AGM.
Ishita Drugs & Industries Ltd will hold a board meeting on September 22, 2026. The meeting will consider raising funds through working capital and term loans.
Ishita Drugs & Industries Ltd has issued physical letters to shareholders with weblinks for its FY 2025-26 Annual Report. The 33rd AGM is scheduled for September 30, 2026.
Ishita Drugs & Industries Ltd has scheduled its 33rd Annual General Meeting for September 30, 2026. The book closure is set from September 24 to September 30, 2026.
Ishita Drugs and Industries Limited has re-appointed Abha Agrawal as a Non-Executive Non-Independent Director, effective October 1, 2026.
Ishita Drugs & Industries Ltd reported revenue from operations of ₹3.1 Cr (-42.6% YoY) and net profit of ₹0.2 Cr (-33.3% YoY) for Q1 FY27.
Ishita Drugs & Industries has scheduled a board meeting for August 8, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Ishita Drugs & Industries Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026, in compliance with SEBI regulations.
Ishita Pharmaceuticals acquired 223 shares of Ishita Drugs & Industries Ltd via open market. The transaction value is approximately ₹0.000223 Crore.
Ishita Drugs & Industries Ltd reported revenue from operations of ₹3.1 Cr (-32.6% YoY) and net profit of ₹0.2 Cr (-33.3% YoY) for Q4 FY26.
Ishita Drugs & Industries approved its FY26 audited financial results showing annual revenue of ₹14.66 Crore. The board also recommended convening the 33rd Annual General Meeting.
Ishita Drugs & Industries Ltd scheduled a board meeting for May 30, 2026. Directors will review audited financial results for the fiscal year ended March 2026.